Note:

Forward-looking statements, such as business forecasts, made in these financial statements are based on managements' estimates, assumptions and projections at the time of publication and do not represent a commitment from Ajinomoto Co., Inc. that they will be achieved. A number of factors could cause actual results to differ materially from expectations.

Unaudited figures are included in this material for reference.

Yen amounts presented in these materials are rounded to the nearest hundred million for amounts in billions and truncated for amounts in millions.

In these materials, "-" indicates that an amount has not been recognized, and "0" indicates a fractional amount due to rounding.

Financial Statement Overview
 A Based on accounting policies applied from FY2014 >

| < Based on accounting policies applied in | UIII F 1 2 U 1 4 > | | | | | | |
|--|--------------------|---------------------|------------------------|-------------------|-----------|-----------------|-----------------|
| | | FY ending | 6 Months | | 6 Months | | |
| | | Mar/15 | ended | FY ended | ended | | |
| | | (projected) | Sept/14 | Mar/14 | Sept/13 | FY ended Mar/13 | FY ended Mar/12 |
| (1) Operating Results | | | | | | | |
| Net Sales* | M. JPY | 1,008,000 | 467,622 | 951,359 | 468,907 | 948,705 | 972,648 |
| Gross profit | M. JPY | 343,400 | 157,921 | 315,765 | 155,267 | 348,075 | 369,227 |
| Operating income | M. JPY | 70,000 | 28,588 | 61,807 | 29,744 | 71,232 | 72,584 |
| Ordinary profit | M. JPY | 75,000 | 31,909 | 68,800 | 33,110 | 77,167 | 75,919 |
| Net income | M. JPY | 44,000 | 20,747 | 42,159 | 22,342 | 48,373 | 41,754 |
| Earnings per share | JPY | 74.32 | 35.04 | 68.67 | 36.06 | 74.35 | 61.28 |
| Return on equity (ROE) | | 7.1% | | 7.1% | | 7.8% | 6.9% |
| Ratio of net income to total assets | | 3.9% | | 3.8% | | | |
| Ratio of operating income to net sale | es | 6.9% | 6.1% | 6.5% | 6.3% | 7.5% | 7.5% |
| Ratio of ordinary income to net sales | 3 | 7.4% | 6.8% | 7.2% | 7.1% | 8.1% | 7.8% |
| (2) Dividends | | | | | | | |
| Dividend per share | | 22 | | 20 | | 18 | 16 |
| Payout ratio | | 29.6% | | 29.1% | | 24.2% | 26.1% |
| (3) Statement of Changes in Financial Po | sition | | | | | | |
| Total assets | M. JPY | 1,117,100 | 1,111,771 | 1,093,165 | 1,070,473 | 1,091,741 | 1,097,057 |
| Net assets | M. JPY | 699,000 | 689,027 | 655,507 | 644,748 | 691,710 | 650,159 |
| Shareholders' equity | M. JPY | 634,000 | 624,127 | 594,950 | 589,104 | 635,287 | 605,349 |
| Shareholders' equity ratio | | 56.8% | 56.1% | 54.4% | 55.0% | 58.2% | 55.2% |
| Book value per share | JPY | 1,071.21 | 1,054.53 | 1,002.29 | 963.26 | 1,004.38 | 894.58 |
| (4) Summary of Cash Flow Statement | - | | | | | | |
| Net cash provided by operating activities | M. JPY | | 56,838 | 63,017 | 19,592 | 88,501 | 93,312 |
| Net cash used in investing activities | M. JPY | | -22,788 | -63,497 | -37,401 | 15,201 | -41,701 |
| Net cash used in financing activities | M. JPY | | -14,546 | -55,248 | -22,686 | -74,419 | -37,456 |
| Cash and cash equivalents at end of period | M. JPY | | 153,780 | 130,028 | 142,548 | 184,770 | 146,647 |
| | | *The following coop | unting policing are of | angod from EV2014 | | | |

The following accounting policies are changed from FY2014.
Sales promotion discounts paid to customers to expand sales are deducted from net sales.
(Figures for FY2011 and subsequent fiscal years have been restated.)

< Based on former accounting policies >

| (1) Operating Results | | |
|---|--------|--|
| Net Sales* | M. JPY | |
| Gross profit | M. JPY | |
| Operating income | M. JPY | |
| Ordinary profit | M. JPY | |
| Net income | M. JPY | |
| Earnings per share | JPY | |
| Return on equity (ROE) | - | |
| Ratio of net income to total assets | | |
| Ratio of operating income to net sales | | |
| Ratio of ordinary income to net sales | | |
| (2) Statement of Changes in Financial Posit | ion | |
| Total assets | M. JPY | |
| Net assets | M. JPY | |
| Shareholders' equity | M. JPY | |
| Shareholders' equity ratio | | |
| Book value per share | JPY | |
| (3) Summary of Cash Flow Statement | | |
| Net cash provided by operating activities | M. JPY | |
| Net cash used in investing activities | M. JPY | |
| Net cash used in financing activities | M. JPY | |
| Cash and cash equivalents at end of period | M. JPY | |

| FY ended | 6 Months ended | | | | |
|---------------------|----------------------|--------------------|---------------------|----------------------|------------------|
| Mar/14 | Sept/13 | FY ended Mar/13 | FY ended Mar/12 | FY ended Mar/11 | FY ended Mar/10 |
| IVIAI/ 14 | Зері/13 | 1 1 ended Wal/13 | 1 1 ended Wal/12 | i i enueu wai/ii | i i ended wai/10 |
| 991,332 | 487,084 | 984,967 | 1,007,208 | 1,015,215 | 982,664 |
| 355,738 | | | | 402,978 | |
| | | | | | |
| 62,548 | | 71,232 | | 69,374 | |
| 69,541 | | | 75,919 | 70,499 | 67,621 |
| 42,795 | 22,179 | 48,373 | 41,754 | 30,400 | 16,646 |
| 69.70 | 35.79 | 74.35 | 61.28 | 43.56 | 23.85 |
| 7.1% | | 7.8% | 6.9% | 5.0% | 2.8% |
| 3.9% | | 4.4% | 3.8% | 2.8% | 1.6% |
| 6.3% | 6.1% | 7.2% | 7.2% | 6.8% | 6.5% |
| 7.0% | 6.8% | 7.8% | 7.5% | 6.9% | 6.9% |
| | | | | | |
| 1,091,650 | 1,069,118 | 1,091,741 | 1,097,057 | 1,077,418 | 1,082,238 |
| 659,487 | 647,928 | 691,710 | 650,159 | 650,291 | 643,179 |
| 598,925 | 592,280 | 635,287 | 605,349 | 608,191 | 602,769 |
| 54.9% | 55.4% | 58.2% | 55.2% | 56.4% | 55.7% |
| 1,008.98 | 968.45 | 1004.38 | 894.58 | 871.61 | 863.72 |
| | | | | | |
| 63,017 | 19,592 | 88,501 | 93,312 | 112,716 | 105,924 |
| -63,497 | -37,401 | 15,201 | -41,701 | -45,882 | -63,327 |
| -55,248 | -22,686 | -74,419 | -37,456 | -25,893 | -18,011 |
| 130,028 | 142,548 | 184,770 | 146,647 | 133,744 | 95,063 |
| *For the coffee and | adible nile husinges | and some other hus | ingeene the arnee f | igures for sales and | , |

*For the coffee and edible oils business and some other businesses, the gross figures for sales and cost of goods sales were recorded in the accounts but from fiscal 2013 this method is changed by netting off sales and cost of goods sold and recording the net figure in the accounts. (Post-reclassification basis from fiscal 2009.)

2. Number of Consolidated Subsidiaries/Affiliates

| Number of Consolidated Subsidiaries/Anniates | | | | | | | | | | |
|--|------------------------------------|------------------------------|--------------------|------------------------------|-----------------|-----------------|-----------------|-----------------|--|--|
| | FY ending Mar/15 (projected) | 6 Months ended Sept/14 | FY ended Mar/14 | 6 Months ended Sept/13 | FY ended Mar/13 | FY ended Mar/12 | FY ended Mar/11 | FY ended Mar/10 | | |
| Consolidated domestic subsidiaries | 39 | 40 | 39 | 39 | 38 | 42 | 41 | 42 | | |
| Consolidated overseas subsidiaries | 51 | 51 | 50 | 50 | 48 | 51 | 54 | 58 | | |
| Sub-Total | 90 | 91 | 89 | 89 | 86 | 93 | 95 | 100 | | |
| Domestic affiliates subject to equity method | 6 | 6 | 6 | 6 | 5 | 4 | 4 | 4 | | |
| Overseas affiliates subject to equity method | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | | |
| Sub-Total | 12 | 12 | 12 | 12 | 11 | 10 | 10 | 10 | | |
| Parent company | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | | |
| Total | 103 | 104 | 102 | 102 | 98 | 104 | 106 | 111 | | |

3. Change of Number of Consolidated Subsidiaries/Affiliates (from Mar/13 to Sept/14)

| J. Cilali | ge of Number of Consolidated Substitutines/Affiliates (| nonimal/13 to Sept/14) |
|-----------|---|---|
| | Increase(2) | Increase: KYODO ACE LOGISTICS CORPORATION, PT Ajinomoto Sales Indonesia |
| | Decrease(0) | Decrease: None |
| Equity me | thod Increase(0) | Increase: None |
| | Decrease(0) | Decrease: None |

4. Foreign Exchange Information

| | | | FY ending Mar/15 | 6 Months ended | FY ended | 6 Months ended | | | | |
|---------------|---------------|---------|---------------------|-------------------|----------|-------------------|-----------------|-----------------|-----------------|-----------------|
| | | | (projected) | Sept/14 | Mar/14 | Sept/13 | FY ended Mar/13 | FY ended Mar/12 | FY ended Mar/11 | FY ended Mar/10 |
| JPY/US Dollar | End of Period | | 100.0 | 109.45 | 102.92 | 97.75 | 94.05 | 82.19 | 83.15 | 93.04 |
| | | Average | 100.0 | 103.01 | 100.17 | 98.86 | 82.91 | 79.08 | 85.74 | 92.89 |
| JPY/Euro | End of Period | | 130.0 | 138.87 | 141.65 | 131.87 | 120.73 | 109.80 | 117.57 | 124.92 |
| | | Average | 130.0 | 138.90 | 134.21 | 129.98 | 106.78 | 109.02 | 113.13 | |
| JPY/THB | End of Period | | 3.20 | 3.38 | 3.17 | 3.11 | 3.20 | 2.67 | 2.75 | 2.87 |
| | | Average | 3.20 | 3.19 | 3.19 | 3.23 | 2.70 | 2.59 | 2.75 | 2.75 |
| JPY/100IDR | End of Period | | 0.8 | 0.90 | 0.91 | 0.85 | 0.98 | 0.91 | 0.96 | 1.03 |
| | | Average | 0.8 | 0.89 | 0.93 | 0.98 | 0.88 | 0.91 | 0.96 | |
| JPY/BRL | End of Period | | 44.0 | 44.71 | 45.52 | 43.40 | 46.52 | 45.12 | 51.05 | 52.47 |
| | | Average | 44.0 | 45.76 | 44.55 | 45.34 | 41.19 | 46.52 | 49.65 | 49.61 |
| JPY/RMB | End of Period | | 16.7 | 17.73 | 16.59 | 15.98 | 15.14 | 13.05 | 12.68 | 13.69 |
| | | Average | 16.7 | 16.62 | 16.38 | 16.10 | 13.18 | 12.36 | 12.78 | 13.60 |

5. Number of Employees

| | FY ending Mar/15 (projected) | 6 Months ended Sept/14 | FY ended Mar/14 | 6 Months ended Sept/13 | EV anded Mar/12 | EV anded Mar/12 | EV anded Mar/11 | FY ended Mar/10 |
|-------------------------|------------------------------------|------------------------------|--------------------|------------------------------|-----------------|-----------------|-----------------|-----------------|
| Parent Company | (projected) | 3.518 | | | | 3.300 | 3.310 | |
| (including expatriates) | | 4,252 | | | | | | 4,175 |
| Consolidated Basis | | 29.829 | 27,579 | 27,600 | 27.518 | 28,245 | 28,084 | 27,215 |

6. Interest-bearing Debts

| | As of Mar/15 (projected) | As of Sept/14 | As of Mar/14 | As of Sept/13 | As of Mar/13 | As of Mar/12 | As of Mar/11 | As of Mar/10 |
|--------------------------------|-----------------------------|---------------|--------------|---------------|--------------|--------------|--------------|--------------|
| Short-term borrowings and debt | | 33,437 | 37,327 | 50,468 | 36,764 | 23,423 | 22,407 | 31,529 |
| Commercial paper | | 15,000 | 0 | 20,000 | 0 | 0 | 0 | 0 |
| Bonds | | 19,994 | 34,993 | 34,993 | 49,992 | 69,990 | 69,989 | 69,988 |
| Long-term debt | | 68,705 | 70,634 | 30,877 | 32,557 | 36,626 | 40,994 | |
| Total | | 137,137 | 142,954 | 136,338 | 119,314 | 130,040 | 133,391 | 147,902 |
| Cash and deposits with bank | | 156,397 | 132,416 | 144,354 | 186,501 | 149,913 | 141,801 | 97,866 |
| Net | | -19,260 | 10,538 | -8,016 | -67,187 | -19,873 | -8,410 | 50,035 |

7. Depreciation

| | FY ending Mar/15 | 6 Months ended | FY ended | 6 Months ended | | | | |
|--------------------------------------|---------------------|-------------------|----------|-------------------|-----------------|-----------------|-----------------|-----------------|
| | (projected) | Sept/14 | Mar/14 | Sept/13 | FY ended Mar/13 | FY ended Mar/12 | FY ended Mar/11 | FY ended Mar/10 |
| (1) Parent company | 92 | 51 | 128 | 63 | 130 | 132 | 156 | 183 |
| Subsidiaries | 362 | 162 | 334 | 164 | 304 | 315 | 356 | 376 |
| Adjustment | - | -2 | -4 | -2 | -9 | -10 | -14 | -5 |
| Total | 454 | 211 | 457 | 225 | 425 | 437 | 498 | 554 |
| (2) By business segment | | | | | | | | |
| Domestic Food Products | 91 | 39 | 96 | 47 | 103 | 129 | 137 | 150 |
| Overseas Food Products | 131 | 64 | 132 | 66 | 98 | 86 | 100 | 104 |
| Bioscience Products & Fine Chemicals | 131 | 64 | 133 | 64 | 113 | 106 | 138 | 182 |
| Pharmaceuticals | 14 | 7 | 21 | 11 | 33 | 37 | 36 | 37 |
| Other Business | 25 | 11 | 21 | 10 | 19 | 22 | 24 | 21 |
| All Company | 61 | 26 | 54 | 27 | 58 | 58 | 64 | |
| Total | 454 | 211 | 457 | 225 | 425 | 437 | 498 | 554 |

Total | 454 | 211 | 457 | 225 |

*In FY2014, the Company change its depreciation method (from the declining balance method to the straight-line method) and revise the terms of useful lives.

*Change of product classification: Medical & Functional foods in Pharmaceuticals

: from Pharmaceuticals to Other Business since FY ended Mar/14.

(Figures for previous periods have not been restated to reflect segment changes.)

8. Capital Expenditure/Investment

| 8. Capital Expenditure/investment | | | | | | | | |
|--------------------------------------|---------------------|-------------------|----------|-------------------|-----------------|-----------------|-----------------|-----------------|
| | FY ending Mar/15 | 6 Months ended | FY ended | 6 Months ended | | | | |
| | (projected) | Sept/14 | Mar/14 | Sept/13 | FY ended Mar/13 | FY ended Mar/12 | FY ended Mar/11 | FY ended Mar/10 |
| (1) Parent company | 128 | 44 | 112 | 53 | 120 | 102 | | |
| Subsidiaries | 492 | 149 | 405 | 169 | 502 | 472 | | |
| Adjustment | - | -6 | -11 | -3 | -6 | -6 | -13 | -0 |
| Total | 620 | 187 | 506 | 219 | 616 | 568 | 458 | 441 |
| (2) By business segment | | | | | | | | |
| Domestic Food Products | 141 | 53 | 85 | 37 | 117 | 123 | 108 | 101 |
| Overseas Food Products | 216 | 45 | 150 | 65 | 235 | 240 | 173 | 134 |
| Bioscience Products & Fine Chemicals | 167 | 60 | 165 | 73 | 163 | 124 | 101 | 115 |
| Pharmaceuticals | 13 | 3 | 13 | 6 | 35 | 32 | 30 | |
| Other Business | 28 | 11 | 26 | 13 | 18 | 20 | 17 | 22 |
| All Company | 55 | 14 | 67 | 25 | | 28 | | |
| Total | 620 | 187 | 506 | 219 | 616 | 568 | 458 | 441 |

^{*}Change of product classification: Medical & Functional foods in Pharmaceuticals : from Pharmaceuticals to Other Business since FY ended Mar/14.

(Figures for previous periods have not been restated to reflect segment changes.)

9. R&D Expenditure

| 9. R&D Expenditure | | | | | | | | |
|--------------------------------------|-------------|----------|----------|----------|-----------------|-----------------|-----------------|-----------------|
| | FY ending | 6 Months | | 6 Months | | | | |
| | Mar/15 | ended | FY ended | ended | | | | |
| | (projected) | Sept/14 | Mar/14 | Sept/13 | FY ended Mar/13 | FY ended Mar/12 | FY ended Mar/11 | FY ended Mar/10 |
| (1) Parent company | 264 | 102 | 241 | 122 | 239 | 245 | 270 | 298 |
| Subsidiaries | 79 | 47 | 77 | 37 | 87 | 104 | 99 | 59 |
| Total | 343 | 148 | 319 | 159 | 326 | 348 | 369 | 356 |
| (2) By business segment | | | | | | | | |
| Domestic Food Products | 35 | 17 | 29 | 14 | 37 | 47 | 60 | 64 |
| Overseas Food Products | 34 | 15 | 28 | 14 | 28 | 30 | 28 | 22 |
| Bioscience Products & Fine Chemicals | 77 | 37 | 75 | 37 | 76 | 76 | 87 | 100 |
| Pharmaceuticals | 67 | 28 | 81 | 40 | 95 | 114 | 112 | 97 |
| Other Business | 8 | 4 | 7 | 3 | 7 | 8 | 12 | 0 |
| All Company | 122 | 46 | 97 | 51 | 84 | 73 | 72 | 73 |
| Total | 343 | 148 | 319 | 159 | 326 | 348 | 369 | 356 |

*Change of product classification: Medical & Functional foods in Pharmaceuticals:
from Pharmaceuticals to Other Business since FY ended Mar/14.
(Figures for previous periods have not been restated to reflect segment in each fiscal year.

10. Selling, G&A Expenses

< Based on accounting policies applied from FY2014 >

| | FY ending Mar/15 (projected) | 6 Months ended Sept/14 | FY ended Mar/14 | 6 Months ended Sept/13 | FY ended Mar/13 | FY ended Mar/12 |
|---|------------------------------------|------------------------------|--------------------|------------------------------|-------------------|--------------------|
| (1) Selling Expense | (projectou) | Соритт | Wall II | Сорыно | 1 1 Oraco mari 10 | T T Gridod Mai/ 12 |
| Transportation | | 17,443 | 31,143 | 15,214 | 32,231 | 35,538 |
| Advertisement | | 11,039 | 21,421 | 10,348 | 22,322 | 22,007 |
| Sales commission | | 10,377 | 24,316 | 11,181 | 39,890 | 50,013 |
| Miscellaneous | | 651 | 1,273 | 702 | 1,259 | 1,068 |
| Total | | 39,512 | 78,155 | 37,446 | 95,703 | 108,627 |
| (2) General and Administrative Expenses | | | | | | |
| Salaries | | 23,412 | 43,989 | 22,313 | 43,955 | 45,238 |
| Bonuses and other allowances | | 9,133 | 17,097 | 8,601 | 17,421 | 18,888 |
| Periodic pension and severance cost | | 3,824 | 5,782 | 2,542 | 6,561 | 8,971 |
| Depreciation expense | | 4,219 | 9,687 | 4,523 | 9,948 | 10,395 |
| Amortization of goodwill* | 1,510 | 769 | 1,589 | 807 | 2,265 | 4,503 |
| Other | | 48,461 | 97,655 | 49,289 | 100,989 | 100,021 |
| Total | | 89,820 | 175,802 | 88,076 | 181,139 | 188,016 |
| Total Selling, G&A expenses | 273,400 | 129,332 | 253,957 | 125,522 | 276,842 | 296,643 |

273,400] 129,332 253,957] 125,522] 276,842
"The following accounting policies are changed from Fry2014.

Sales promotion discounts paid to customers to expand sales are deducted from net sales.
(Figures for Fry2011 and subsequent fiscal years have been restated.)

"Names and definitions of items in the breakdown of sales expenses have been changed from fiscal 2014.
(Figures for Fry2011 and subsequent fiscal years have been restated.)

| < Based on former | accounting | policies | > |
|-------------------|------------|----------|---|
|-------------------|------------|----------|---|

| (1) Selling Expense | |
|---|-----------------------------|
| Transportation | |
| Advertisement | |
| Sales commission | |
| Miscellaneous | |
| | Tota |
| (2) General and Administrative Expenses | |
| Salaries | |
| Bonuses and other allowances | |
| Periodic pension and severance cost | |
| Depreciation expense | |
| Amortization of goodwill* | |
| Other | |
| | Tota |
| | Total Selling, G&A expenses |

| FY ended Mar/14 | 6 Months ended Sept/13 | FY ended Mar/13 | FY ended Mar/12 | FY ended Mar/11 | FY ended Mar/10 |
|--------------------|------------------------------|-----------------|-----------------|-----------------|-----------------|
| | | | | | |
| 29,356 | 14,356 | 31,423 | 34,265 | 33,450 | 31,675 |
| 30,330 | 14,717 | 32,700 | 32,571 | 33,628 | 34,213 |
| 40,688 | 19,246 | 53,681 | 61,331 | 62,089 | 58,560 |
| 24,433 | 11,531 | 22,552 | 22,257 | 23,809 | 23,606 |
| 124,808 | 59,853 | 140,357 | 150,425 | 152,978 | 148,055 |
| | | | | | |
| 43,989 | 22,313 | 43,955 | 45,238 | 42,981 | 42,847 |
| 17,097 | 8,601 | 17,421 | 18,888 | 17,898 | 16,938 |
| 5,782 | 2,542 | 6,561 | 8,971 | 9,484 | 8,365 |
| 9,687 | 4,523 | 9,948 | 10,395 | 10,543 | 9,583 |
| 1,589 | 807 | 2,265 | 4,503 | 4,505 | 5,000 |
| 90,235 | 45,283 | 92,594 | 92,781 | 95,211 | 90,472 |
| 168,381 | 84,070 | 172,747 | 180,777 | 180,625 | 173,208 |
| 293,190 | 143,923 | 313,104 | 331,203 | 333,604 | 321,264 |

11. Non-Operating Income & Loss

| 11. Non-Operating income & Loss | | | | | | | | |
|----------------------------------|------------------------------------|------------------------------|--------------------|------------------------------|-----------------|-----------------|-----------------|-----------------|
| | FY ending Mar/15 (projected) | 6 Months ended Sept/14 | FY ended Mar/14 | 6 Months ended Sept/13 | FY ended Mar/13 | FY ended Mar/12 | FY ended Mar/11 | FY ended Mar/10 |
| (1) Non-Operating Income | (1-1)-1-1-1 | | | | | | | |
| Interest income | | 1,383 | 2,129 | - | 1,857 | 1,847 | 1,232 | 1,162 |
| Dividend income | | 700 | 1,067 | - | 1,044 | 974 | 939 | 1,012 |
| Equity in earnings of affiliates | | 2,128 | 3,360 | 1,865 | 3,058 | 2,401 | 2,990 | |
| Exchange gains | | - | 0 | | 0 | 0 | 0 | 2,639 |
| Other | | 1,840 | 5,030 | 3,985 | 3,983 | 2,263 | 2,250 | |
| Total | 7 | 6,053 | 11,588 | 5,850 | 9,944 | 7,487 | 7,411 | 10,931 |
| (2) Non-Operating Expense | | | | | | | | |
| Interest expense | | 1,061 | 2,032 | 1,080 | 1,931 | 2,167 | | |
| Exchange losses | | - | - | - | 0 | 0 | 205 | |
| Other | | 1,671 | 2,563 | 1,404 | 2,077 | 1,985 | 3,639 | |
| Total | 7 | 2,732 | 4,595 | 2,484 | 4,009 | 4,152 | 6,286 | 7,344 |

| 1H-F Y2014 Consolidated Results | | | | | | | | | |
|---|--------|------------------------------------|------------------------------|--------------------|------------------------------|-----------------|-----------------|-----------------|-----------------|
| 12. Extraordinary Items | | | | | | | | | |
| | | FY ending Mar/15 (projected) | 6 Months ended Sept/14 | FY ended Mar/14 | 6 Months ended Sept/13 | FY ended Mar/13 | FY ended Mar/12 | FY ended Mar/11 | FY ended Mar/10 |
| (1) Extraordinary Gains | | | (| | | | | | |
| Gain on prior period adjustment | | / | - | - | - | - | 0 | 0 | 1,322 |
| Gain on sales of fixed assets | | / | - | 3,081 | - | 0 | 0 | 0 | 0 |
| Gain on sales of investment securities | | | - | 0 | - | 0 | 554 | 912 | 0 |
| Gain on sales of investments in affiliates | | / | - | 2,315 | 2,267 | 18,201 | 0 | 0 | 0 |
| Reversal of accrued expense on contract alteration | | / | - | - | - | - | 0 | 0 | 1,437 |
| Cancellation money | | / | - | | - | - | 0 | 0 | 0 |
| Insurance income | | / | 10 | 1,189 | 1,190 | 1,800 | 6,012 | 182 | 0 |
| Gain on transfer of benefit obligation relating to employees' pension fund | | / | _ | - | - | 27,752 | 0 | 0 | 0 |
| Gain on bad debts recovered | | | 581 | - | - | _ | _ | - | _ |
| Other | | / | 316 | 2,036 | 250 | 1,837 | 521 | 2,126 | 609 |
| To | otal | / | 908 | 8,621 | 3,708 | 49,141 | 7,088 | | 3,368 |
| (2) Extraordinary Losses | | -/- | | | | - 1 | ,,,,, | -,- | ., |
| Loss on disposal of fixed assets | | | 505 | 1,222 | 662 | 2,951 | 3,320 | 0 | 4,536 |
| Impairment losses | | | - | 624 | - | 14,562 | 1,106 | 8,503 | 14,325 |
| Loss on sales of fixed assets | | 1 | - | 0 | - | 0 | 0 | 0 | 0 |
| Loss on devaluation of securities | | / | - | 0 | - | 2,346 | 607 | 7,416 | 0 |
| Retirement benefit expenses | | / | - | 0 | - | 0 | 0 | 0 | 0 |
| Loss on devaluation of investments in affiliates | | / | - | 0 | - | 0 | 0 | 0 | 0 |
| Loss on liquidation of affiliates | / | / | - | 859 | 702 | 0 | 0 | 0 | 0 |
| Loss from natural disaster | | | - | | - | 0 | 3,759 | | 0 |
| Other | 1/ | | 838 | 2,155 | 670 | 7,966 | 2,121 | 6,123 | 7,337 |
| To | otal / | | 1,343 | 4,860 | 2,036 | 25,481 | 10,915 | 25,275 | 26,198 |

13. Information by Business segment

< Based on former accounting policies >

| 13. Information by Business segment | | | | | | |
|--|-------------|----------|----------|----------|-----------------|---------------------|
| < Based on accounting policies applied from FY2014 > | | | , in | | | (in millions of JPY |
| | FY ending | 6 Months | | 6 Months | | |
| | Mar/15 | ended | FY ended | ended | | |
| | (projected) | Sept/14 | Mar/14 | Sept/13 | FY ended Mar/13 | FY ended Mar/12 |
| Domestic Food Products | | | | | | |
| Sales to external customers | 312,300 | 147,298 | 299,925 | 144,282 | 357,057 | 396,268 |
| Y/Y % | 104% | 102% | 84% | - | 90% | - |
| Operating income | 28,800 | 10,107 | 27,056 | 11,368 | 32,641 | 31,705 |
| Y/Y % | 106% | 89% | 83% | - | 103% | - |
| Overseas Food Products | | | | | | |
| Sales to external customers | 322,200 | 153,135 | 292,366 | 144,073 | 245,085 | 229,960 |
| Y/Y % | 110% | 106% | 119% | - | 107% | - |
| Operating income | 29,400 | 16,421 | 25,042 | 12,801 | 20,703 | 21,545 |
| Y/Y % | 117% | 128% | 121% | - | 96% | - ' |
| Bioscience Products & Fine Chemicals | | | | | | |
| Sales to external customers | 238,400 | 108,265 | 228,102 | 111,629 | 203,801 | 197,648 |
| Y/Y % | 105% | 97% | 112% | - | 103% | - |
| Operating income | 9,700 | 2,573 | 6,390 | 3,879 | 14,368 | 12,159 |
| Y/Y % | 152% | 66% | 44% | - | 118% | - |
| Pharmaceuticals | | | | | | |
| Sales to external customers | 40,900 | 18,793 | 51,228 | 27,899 | 71,450 | 77,922 |
| Y/Y % | 80% | 67% | 72% | - | 92% | - |
| Operating income | 2,300 | 235 | 3,811 | 1,531 | 3,194 | 6,488 |
| Y/Y % | 60% | 15% | 119% | - | 49% | - |
| Other Business | | | | | | |
| Sales to external customers | 94,200 | 40,129 | 79,736 | 41,022 | 71,312 | 70,847 |
| Y/Y % | 118% | 98% | 112% | - | 101% | - |
| Operating income | -200 | -750 | -493 | 163 | 324 | 686 |
| Y/Y % | 41% | - | - | - | 47% | - |
| Consolidated, Total | | | | | | |
| Net Sales | 1,008,000 | 467,622 | 951,359 | 468,907 | 948,705 | 972,648 |
| Y/Y % | 106% | 100% | 100% | - | 98% | - ' ' |
| Operating income | 70,000 | 28,588 | 61,807 | 29,744 | 71,232 | 72,584 |
| Y/Y % | 113% | 96% | 87% | _ | 98% | - |

113% 96% 87% - The following accounting policies are changed from FY2014.
Sales promotion discounts paid to customers to expand sales are deducted from net sales. (Figures for FY2011 and subsequent fiscal years have been restated.)

| Domestic Food Products | |
|--------------------------------------|--|
| Sales to external customers | |
| Y/Y % | |
| Operating income | |
| Y/Y % | |
| Overseas Food Products | |
| Sales to external customers | |
| Y/Y % | |
| Operating income | |
| Y/Y % | |
| Bioscience Products & Fine Chemicals | |
| Sales to external customers | |
| Y/Y % | |
| Operating income | |
| Y/Y % | |
| Pharmaceuticals | |
| Sales to external customers | |
| Y/Y % | |
| Operating income | |
| Y/Y % | |
| Other Business | |
| Sales to external customers | |
| Y/Y % | |
| Operating income | |
| Y/Y % | |
| Consolidated, Total | |
| Net Sales | |
| Y/Y % | |
| Operating income | |
| Y/Y % | |

| FY ended | 6 Months ended | | | | |
|----------|-------------------|-----------------|-----------------|-----------------|-----------------|
| Mar/14 | Sept/13 | FY ended Mar/13 | FY ended Mar/12 | FY ended Mar/11 | FY ended Mar/10 |
| | | | | | |
| 337,533 | 161,177 | 391,554 | 428,996 | 427,707 | 425,749 |
| 86% | 73% | 91% | 100% | 100% | - |
| 27,429 | 10,961 | 32,641 | 31,705 | 26,506 | 24,311 |
| 84% | 63% | 103% | 120% | 109% | - |
| | | | | | |
| 293,237 | 144,501 | 245,397 | 230,541 | 231,990 | 214,613 |
| 119% | 126% | 106% | 99% | 108% | - |
| 25,231 | 12,877 | 20,703 | 21,545 | 26,837 | 25,465 |
| 122% | 126% | 96% | 80% | 105% | - |
| | | | | | |
| 228,528 | 111,816 | 204,206 | 198,021 | 198,291 | 193,553 |
| 112% | 115% | 103% | 100% | 102% | - |
| 6,530 | 3,923 | 14,368 | 12,159 | 8,685 | 5,252 |
| 45% | 54% | 118% | 140% | 165% | - |
| | | | | | |
| 51,228 | 27,899 | 71,450 | 77,922 | 82,645 | 82,594 |
| 72% | 78% | 92% | 94% | 100% | - |
| 3,842 | 1,546 | 3,194 | 6,488 | 7,940 | 12,353 |
| 120% | 86% | 49% | 82% | 64% | - |
| | | | | | |
| 80,804 | 41,690 | 72,358 | 71,727 | 74,579 | 66,155 |
| 112% | 112% | 101% | 96% | 113% | - |
| -485 | 213 | 324 | 686 | -595 | -3,347 |
| - | 74% | 47% | , | 18% | - |
| | | | | | |
| 991,332 | 487,084 | 984,967 | 1,007,208 | 1,015,215 | 982,664 |
| 101% | 96% | 98% | 99% | 103% | - |
| 62,548 | 29,521 | 71,232 | 72,584 | 69,374 | 64,034 |
| 88% | 80% | 98% | 105% | 108% | - ' |

^{| 88% | 98% | 105% | 108% | 108% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 208% | 20}

14. Information by Geographic segment

| < Based on accounting policies applied from FY2014 > | | | | | | (in millions of JPY) |
|--|------------------------------------|------------------------------|--------------------|------------------------------|-----------------|----------------------|
| | FY ending Mar/15 (projected) | 6 Months ended Sept/14 | FY ended Mar/14 | 6 Months ended Sept/13 | FY ended Mar/13 | FY ended Mar/12 |
| Japan | | | | | | |
| Sales to external customers | 481,700 | 225,339 | 474,948 | 235,602 | | 590,828 |
| Y/Y % | 101% | 96% | 88% | - | 92% | - |
| Operating income | 30,700 | 11,882 | 32,724 | 14,155 | | 35,555 |
| Y/Y % | 94% | 84% | 95% | - | 97% | - |
| Asia | | | | | | |
| Sales to external customers | 259,300 | 120,334 | 230,269 | 115,236 | | 177,396 |
| Y/Y % | 113% | 104% | 118% | - | 110% | - |
| Operating income | 29,500 | 14,945 | 24,847 | 13,280 | | 21,585 |
| Y/Y % | 119% | 113% | 112% | - | 102% | - |
| Americas | | | | | | |
| Sales to external customers | 159,500 | 72,043 | 139,287 | 68,078 | | 114,084 |
| Y/Y % | 115% | 106% | 119% | - | 103% | - |
| Operating income | 9,400 | 3,130 | 4,197 | 2,655 | | 8,888 |
| Y/Y % | 224% | 118% | 45% | - | 104% | - |
| Europe | | | | | | |
| Sales to external customers | 107,500 | 49,904 | 106,853 | 49,990 | | 90,338 |
| Y/Y % | 101% | 100% | 112% | - | 105% | - |
| Operating income | 400 | -1,369 | 37 | -347 | 5,491 | 6,554 |
| Y/Y % | 1081% | - | 1% | - | 84% | - |
| Consolidated, Total | | | | | | |
| Sales to external customers | 1,008,000 | 467,622 | 951,359 | 468,907 | 948,705 | 972,648 |
| Y/Y % | 106% | 100% | 100% | - | 98% | - |
| Operating income | 70,000 | 28,588 | 61,807 | 29,744 | 71,232 | 72,584 |
| Y/Y % | 112% | 96% | 87% | - | 98% | - |

< Based on former accounting policies >

| I** | |
|-----------------------------|--|
| Japan** | |
| Sales to external customers | |
| Y/Y % | |
| Operating income | |
| Y/Y % | |
| Asia | |
| Sales to external customers | |
| Y/Y % | |
| Operating income | |
| Y/Y % | |
| Americas | |
| Sales to external customers | |
| Y/Y % | |
| Operating income | |
| Y/Y % | |
| Europe | |
| Sales to external customers | |
| Y/Y % | |
| Operating income | |
| Y/Y % | |
| Consolidated, Total | |
| Sales to external customers | |
| Y/Y % | |
| Operating income | |
| V/V % | |

| | | | | | 1 |
|----------|----------|-----------------|-----------------|-----------------|-----------------|
| | 6 Months | | | | |
| FY ended | ended | | | | |
| Mar/14 | Sept/13 | FY ended Mar/13 | FY ended Mar/12 | FY ended Mar/11 | FY ended Mar/10 |
| | • | | | | |
| 514,048 | 253,350 | 577,458 | 624,808 | 638,329 | 624,245 |
| 89% | 80% | 92% | 98% | 102% | 96% |
| 33,163 | 13,551 | 34,350 | 35,555 | 32,269 | 30,313 |
| 97% | 73% | 97% | 110% | 106% | 123% |
| | | | | | |
| 231,143 | 115,665 | 194,846 | 177,977 | 174,836 | 159,795 |
| 119% | 126% | 109% | 102% | 109% | 106% |
| 24,999 | 13,508 | 22,105 | 21,585 | 21,226 | 21,734 |
| 113% | 118% | 102% | 102% | 98% | 199% |
| | | | | | |
| 139,287 | 68,078 | 117,483 | 114,084 | 113,556 | 105,437 |
| 119% | 122% | 103% | 100% | 108% | 99% |
| 4,282 | 2,750 | 9,285 | 8,888 | 7,551 | 5,875 |
| 46% | 58% | 104% | 118% | 129% | 102% |
| | | | | | |
| 106,853 | 49,990 | 95,178 | 90,338 | 88,491 | 93,187 |
| 112% | 119% | 105% | 102% | 95% | 104% |
| 102 | -289 | 5,491 | 6,554 | 8,327 | 6,112 |
| 2% | -13% | 84% | 79% | 136% | - |
| | | | | | |
| 991,332 | 487,084 | 984,967 | 1,007,208 | 1,015,213 | 982,664 |
| 101% | 96% | 98% | 99% | 103% | 98% |
| 62,548 | 29,521 | 71,232 | 72,584 | 69,374 | 64,034 |
| 88% | 80% | 98% | 105% | 108% | 157% |

 ^{88% | 98% | 105% | 105%} Change of product classification:
 Domestic Food Products: Previous years' figures for Kellogg's products restated as net sales less cost of sales.
 Medical foods: Moved from Pharmaceuticals to Other Business (figures for previous years not restated).

Pharmaceuticals: Sales decreased due to transfer of Infusions and dialysis business in July 2013.